Rona Therapeutics

What Rona Therapeutics does

Rona Therapeutics is a Shanghai-headquartered, clinical-stage biopharmaceutical company founded in 2021 that develops RNA interference (RNAi) therapeutics using small interfering RNA (siRNA) technology. The company builds its drug candidates on four proprietary technology platforms: GAIA, a GalNAc-conjugated liver-targeting delivery platform enabling long dosing intervals; APOLLO, a small-molecule-conjugated extrahepatic delivery platform with CNS proof-of-concept in non-human primates and intrathecal administration capability; Bi-Valent/Multi-Valent, a plug-and-play scalable platform for simultaneous multi-target silencing in complex diseases such as cardiovascular disease and obesity; and RAZOR, a discovery engine for differentiated siRNA design. Its clinical pipeline targets genetically validated cardiometabolic and metabolic disease drivers — RN0191 (PCSK9, hypercholesterolemia), RN0361 (APOC3, hypertriglyceridemia), RN3161 (INHBE, obesity), RN1871 (AGT, hypertension), and RN5681 (bi-valent PCSK9-LPA, ASCVD) — alongside earlier-stage CNS, renal, and MASH programs. The company is led by founder/CEO Stella Shi (formerly MD at Lilly Asia Ventures) and CMO Dr. Alex M. DePaoli (former Head of Cardiometabolic TA at Amgen), and operates globally with R&D in Shanghai, clinical operations in Melbourne, Australia, and a US subsidiary incorporated in Delaware.

The business model is a classic clinical-stage biotech framework: Rona is pre-revenue and does not currently sell commercial products, generating no disclosed top-line. Long-term revenue is expected to flow from licensing royalties, co-development milestone payments, and profit-sharing arrangements with pharmaceutical partners, supplemented by potential future direct commercialization. Co-development collaborations are already in place with Keymed Biosciences for glomerulonephritis siRNA (global profit/loss split, signed May 2023) and EnnovaBio Pharmaceuticals for liver disease targets (signed January 2023, using the RAZOR platform). The company has raised approximately $200 million USD across a $33M Series A (April 2022), a $35M Series A+ led by LongRiver Investments (July 2024), and a $25M Pre-B led by Guanghua Wutong Fund (March 2025), from blue-chip healthcare investors including Lilly Asia Ventures, CMB International, Fontus Capital, Lanting Capital, Zhaode Investment, BioTrack Capital, and Zhongqi Capital. Rona pursues an enterprise-focused go-to-market via multi-jurisdictional clinical trial execution, scientific conference presentations (AHA, AASLD, OTS, EASL), peer-reviewed publications, and strategic partnership BD aimed at attracting pharmaceutical licensing or co-development partners for late-stage assets.

Rona serves four primary patient/customer segments defined by unmet medical need in cardiometabolic, metabolic, renal, and CNS diseases, rather than identifiable institutional buyers: cardiovascular disease and hypercholesterolemia patients, hypertriglyceridemia patients, obesity/overweight populations (positioned against GLP-1 adherence and muscle-loss drawbacks), and hypertension patients, with secondary segments in neurodegenerative disease (Alzheimer's, epilepsy, ALS) and chronic kidney disease (IgA nephropathy, lupus nephritis, membranous nephropathy). The company's commercial value proposition rests on enabling potent, durable gene silencing with Q6M–Q12M subcutaneous or intrathecal dosing — a structurally lower-burden regimen than incumbent daily oral therapies — and on proprietary chemistry that has produced clinical-stage readouts of up to 95% target protein knockdown with sustained effect at six months from a single dose.

Name

Rona Therapeutics

Legal name

Rona Therapeutics

Website

https://ronatherapeutics.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Rona Therapeutics is a Shanghai-based, clinical-stage biopharmaceutical company developing siRNA therapeutics via proprietary GAIA (liver), APOLLO (CNS/extrahepatic), and Bi-Valent delivery platforms for cardiometabolic, renal, and neurodegenerative diseases.

Ownership category

akta.pro rank

Product category

RNA-based Therapeutics (siRNA Biopharmaceuticals)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

akta.pro secondary industries

RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI), Neurology/CNS Gene Therapies (HLAAACAH)

Keywords

• SiRNA therapeutics
• RNA interference drugs
• Cardiometabolic drug development
• Oligonucleotide delivery platforms
• Gene silencing medicines

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Drug Development and Licensing: As a clinical-stage biopharmaceutical company, Rona Therapeutics is pre-revenue. The company develops proprietary siRNA therapeutics and may generate revenue through licensing agreements, co-development partnerships, or eventual product commercialization following regulatory approvals.
2. Strategic Partnerships and Collaborations: The company enters into co-development and co-commercialization arrangements with pharmaceutical partners (e.g., Keymed Biosciences, EnnovaBio Pharmaceuticals) that may include upfront payments, milestone payments, and profit-sharing arrangements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Rona Therapeutics develops clinical-stage siRNA (small interfering RNA) therapeutics for cardiometabolic, renal, and neurodegenerative diseases. Its pipeline is built on proprietary delivery platforms — GAIA for liver targeting, APOLLO for CNS/extrahepatic delivery, and Bi-Valent/Multi-Valent for multi-target silencing — and includes drug candidates such as RN0191 (PCSK9), RN0361 (APOC3), RN3161 (INHBE), RN5681 (PCSK9-LPA), and RN1871 (AGT) designed for long-acting, infrequent subcutaneous or intrathecal dosing.

Product overview

Rona Therapeutics is an siRNA therapeutics platform company developing a portfolio of RNA-based drugs for metabolic and neurodegenerative diseases. The company's product portfolio centers on its proprietary delivery platforms: GAIA (liver-targeted GalNAc conjugation), APOLLO (extrahepatic CNS delivery), and Bi-Valent/Multi-Valent (scalable platform for complex diseases). Key clinical-stage candidates include RN0191 (PCSK9 for hypercholesterolemia), RN0361 (APOC3 for hypertriglyceridemia), RN3161 (INHBE for obesity), RN5681 (bi-valent PCSK9-LPA for cardiovascular risk), and RN1871 (AGT for hypertension). The company also has pipeline programs for cardiomyopathy (RN3271), IgAN (RNK288), MASH (RNN798), and CNS disorders (RN276, RN201) utilizing its APOLLO platform.

Differentiator

Problem solved

Functional benefit

Products and services

• RN0191 PCSK9-targeting siRNA therapeutic for hypercholesterolemia, mixed hyperlipidemia, and atherosclerotic cardiovascular disease, built on the GAIA liver delivery platform. Demonstrated up to 95% individual maximum and 87% mean maximum PCSK9 reduction with up to 74% LDL-C lowering in Phase 1 trials and durable effects maintained through 6 months supporting bi-annual dosing. Has received IND approval from China NMPA and ethics approval in Australia.
• RN0361 Long-acting APOC3-targeting siRNA therapeutic for severe hypertriglyceridemia, mixed dyslipidemia, and familial chylomicronemia syndrome. Achieved 93% ApoC3 reduction and 69% triglyceride lowering lasting at least six months from a single dose in Phase 1 trials. Has received Australian Phase 1 approval and FDA IND clearance for Phase 2.
• RN3161 INHBE-targeting siRNA therapeutic for obesity treatment, designed for once- or twice-yearly dosing with preserved lean mass, leveraging GAIA-platform GalNAc conjugation and novel chemical modifications. Showed more than 90% INHBE mRNA knockdown in monkeys at low single dose. IND filed with Australian HREC in September 2025 and completed Phase 1 Cohort 1 dosing in December 2025.
• RN1871 AGT (angiotensinogen)-targeting siRNA therapeutic for hypertension. Silences AGT mRNA expression in the liver to inhibit Renin-Angiotensin-Aldosterone System precursor protein production. Received NMPA IND approval for Phase 1 study in April 2025.
• RN5681 First-in-class bi-valent PCSK9-LPA siRNA designed to simultaneously silence both PCSK9 and LPA for atherosclerotic cardiovascular disease, aiming to deliver deep, durable lipid improvement and address residual cardiovascular risk. Submitted to Australian HREC for Phase 1 clinical development in December 2025.

Quantifiable outcome

• RN0191 achieved up to 95% individual maximum and 87% mean maximum PCSK9 reduction, and up to 74% individual maximum and 56% mean maximal LDL-C lowering, with durable effects maintained through 6 months supporting bi-annual dosing
• +3 more outcomes

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Keymed BiosciencescoreStrategic or Co-development Partner · 15 May 2023Co-development collaboration announced May 15, 2023 to jointly discover and develop first-in-class siRNA therapeutics for glomerulonephritis (severe kidney diseases). Keymed (HKEX: 02162) contributes research and translational expertise. The partnership includes profit/loss arrangement for global co-development and commercialization. Program expected to enter clinical stage in 2024.
• EnnovaBio PharmaceuticalscoreStrategic or Co-development Partner · 12 January 2023Co-development collaboration announced January 12, 2023 to discover and develop first-in-class siRNA therapeutics for liver diseases associated with metabolism. Rona uses its proprietary RAZOR platform while EnnovaBio contributes drug discovery expertise, translational capabilities, and eSTEM target assessment platform. The partnership aims to target 'undruggable' liver disease targets using next-generation siRNA technology.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Ionis Pharmaceuticals: Ionis is the established leader in antisense oligonucleotide (ASO) therapeutics with multiple approved products. Although it uses ASOs rather than siRNA, it pursues similar cardiometabolic and rare disease targets with comparable liver-targeted delivery chemistry.
• Amgen: Amgen developed Repatha (PCSK9 monoclonal antibody), and Rona's CMO previously led the PCSK9 program at Amgen. Amgen is a key competitor in the cardiovascular lipid-lowering space where Rona's RN0191 and RN5681 compete.

Direct peers

• Alnylam Pharmaceuticals: Alnylam is the global siRNA therapeutics leader with approved products including Leqvio (PCSK9, partnered with Novartis) which directly competes with Rona's RN0191. Both companies pursue GalNAc-conjugated liver-targeted siRNA and target cardiometabolic indications.
• Dicerna Pharmaceuticals (Novo Nordisk): Dicerna (acquired by Novo Nordisk in 2021) developed GalXC siRNA platform targeting cardiometabolic and rare diseases. Its cardiometabolic pipeline and GalNAc-based liver delivery are highly comparable to Rona's GAIA platform.
• Wave Life Sciences: Wave Life Sciences is a clinical-stage RNA therapeutics company developing siRNA and other oligonucleotide modalities. It shares Rona's focus on next-generation RNA chemistry modifications and extrahepatic delivery, making it a directly comparable platform-stage peer.
• Arrowhead Pharmaceuticals: Arrowhead develops multiple RNAi therapeutics including cardiometabolic siRNA programs targeting APOC3, AGT, and other validated targets overlapping with Rona's pipeline. Both use proprietary delivery platforms and pursue subcutaneous liver-targeted delivery with extended dosing intervals.
• Sirnaomics: Sirnaomics is a China- and US-based clinical-stage biopharmaceutical company developing siRNA therapeutics, including programs in cardiovascular and metabolic indications. It is the closest China-domiciled peer to Rona in therapeutic area and platform technology.
• Silence Therapeutics: Silence Therapeutics is a clinical-stage siRNA company with programs in cardiovascular and hematological diseases using GalNAc-conjugated siRNA. Its cardiometabolic pipeline and platform approach are directly comparable to Rona's GAIA liver-targeted platform.
• Suzhou Ribo Life Science: Suzhou Ribo is a Chinese clinical-stage siRNA company developing oligonucleotide-based therapeutics for metabolic and rare diseases. It is a regional peer sharing Rona's China-based clinical development approach and target focus.

Emerging players

• Marea Therapeutics: Marea Therapeutics is an early-stage cardiometabolic-focused company where Rona's CMO Alex DePaoli previously served as CMO. It develops oligonucleotide-based therapies for cardiometabolic disease, overlapping with Rona's RN0191 PCSK9 program and broader cardiometabolic positioning.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ronatherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rona Therapeutics